Icrucumab (IMC-18F1) is a human monoclonal antibody designed for the treatment of solid tumors.[1][2]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | VEGFR-1 |
Clinical data | |
Other names | IMC-18F1 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6514H10024N1756O2032S42 |
Molar mass | 146796.63 g·mol−1 |
![]() ![]() |
Icrucumab was developed by ImClone Systems Inc. It is undergoing Phase I trials.[3]
References
edit- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab" (PDF). American Medical Association.
- ^ LoRusso PM, Krishnamurthi S, Youssoufian H, Hall N, Fox F, Dontabhaktuni A, Grebennik D, Remick S (April 2014). "Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study". Invest New Drugs. 32 (2): 303–11. doi:10.1007/s10637-013-9998-8. PMID 23903897. S2CID 34756277.
- ^ Clinical trial number NCT00782002 for "Safety Study of IMC-18F1, to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy" at ClinicalTrials.gov
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.